First Long-Acting Injectable HIV Treatment Works Better Than Daily Pills For Some Patients, GSK SaysForbes • 02/21/24
GSK Exercises Option to License Elsie Biotechnologies' Discovery Platform to Find and Develop Novel OligonucleotidesBusiness Wire • 02/14/24
GSK: American investment bank goes positive on the stock for the first time in seven years. Here's whyProactive Investors • 02/13/24
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less riskMarket Watch • 02/12/24
GSK's RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased RiskBusiness Wire • 02/06/24